Narcolepsy with Cataplexy

Disease

Related News

Takeda Advances Two Neuroscience Clinical Trials: Narcolepsy and Teen Depression

Jun 11, 2026

Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.

GSK Licenses Linerixibat to Alfasigma for $690M; Eisai's E2086 Receives Orphan Designation

Mar 09, 2026

GSK agreed to license linerixibat to Alfasigma in a deal worth up to $690 million, while Eisai received orphan drug designation in Japan for E2086, a novel selective orexin 2 receptor agonist for narcolepsy.